NOVEMBER 2008
Daniel Libeskind & Thomas Friedman graduate with honors
Presented with a Technion Honorary Doctorate of Science in June 2008...
Route to alternative energy technologies
An innovative interdisciplinary course, “Clean Energy: Technology under Policy and Economic Constraints,”... 
Out of sight
Technion is a first stop for high-tech firms seeking excellence in research. A new Vision Systems Research initiative in the Faculty of Electrical...
Campus Technion in the Headlines Research Environment Technology Transfer Outreach
> Printable version
> View previous issues
News Flash
Technion Trail: Tour of Campus Sculptures
21/04/2010, Read more
Watch How One Cornerstone Changed the World
19/06/2011, Read more
Israel -- One Hundred Years of Science and Technology Film
25/07/2011, Read more
Technion and Microsoft Co-establish Academic Research Center For E-Commerce Technologies
10/10/2011, Read more
Google Street View Puts Technion on the Map
17/10/2011, Read more
Small Things Come in Big Packages: Video
09/11/2011, Read more
International Caricature Exhibition Shows in Ullmann Teaching Center
10/11/2011, Read more
Harvey Prize 2011 Winners Announced
13/11/2011, Read more
New videos: Richard Karp and Ronny Lempel
21/11/2011, Read more
German Order of Merit to Distinguished Prof. Yitzhak Apeloig
29/11/2011, Read more
View news archive
CERN 2008 - On site at CERN
“ATLAS,” says Technion Prof. Shlomit Tarem, “is the biggest experiment searching for the smallest things.” She is referring to the biggest of the six particle detector experiments constructed at the Large Hadron Collider (LHC), a particle accelerator at CERN (European Organization for Nuclear Research) in Switzerland. Read more
Azilect©. The proof is in
The results of a phase III clinical trial dubbed ADAGIO show that Azilect® 1mg once-daily tablets slow down Parkinson’s disease (PD). Patients who took this dose upon entry into the 18-month trial demonstrated a significant improvement compared to those who only started taking the drug after nine months. Results were presented in August 2008 at the 12th Congress of European Federation of Neurological Societies in Madrid.
The ADAGIO trial, the first of its kind and one of the largest for PD, encompassed 1,176 patients in 14 countries. Based on these latest results, Azilect® could become the first PD treatment to receive a label for disease modification as no other current therapy acts as an agent to slow the disease’s progression.

Technion Profs. Moussa Youdim and John Finberg of the Rappaport Faculty of Medicine developed the drug with Teva Pharmaceutical Industries Ltd.
Einstein in the lab
Prof. Albert Einstein‚ Technion founding father‚ predicted that if you make atoms cold enough, they could go into the same state, operating as a wave rather than as individual atoms. This was proven experimentally a decade ago, and the 2001 Nobel Prize in Physics was received for this proof. On an upper floor of Technion’s Albert Einstein Institute of Physics, in a perfectly attuned, sophisticated self-built lab, Dr Jeff Steinhauer is exploring the properties of these waves, taking Bose-Einstein Condensation experimentation to another league. Entering the Steinhauer-pioneered atomic physics laboratory is a sensitive procedure: nothing there should be nudged or touched, a nanometer movement of the apparatus could sabotage weeks of experimentation. It is a gasp-worthy place, where atoms are cooled to temperatures close to absolute zero, and are observed to pass through physical barriers as a wave, as if the “wall” were not there. Read more
© 2009 Technion-Israel Institute of Technology, Division of Public Affairs and Resource Development
All rights reserved. If you wish to use any text or graphics contained herein, please contact focus@tx.technion.ac.il